MARKETS / ADAPY
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Adaptimmune Therapeutics PLC ADAPY
11 fiscal years on record · USD · FY2024 reported · SEC filings only
Growth
USD 178.0M
Revenue, FY2024 · full 11-year series below
Revenue $M
Net income $M
FY2024 · Revenue 178.0 · Net income -70.8
Compound annual growth
Revenue compounded at +175.5% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−40 cents
lost on every revenue dollar
Operating margin
Net margin
FY2024 · Operating -38.6% · Net -39.8%
ROE
FY2024 · ROE -275.7%
Each USD of equity lost 276 cents this year.
The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.1 | −0.2 | 0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | 0.0 |
| EPS, diluted $ | −0.05 | −0.09 | −0.17 | −0.17 | −0.15 | −0.22 | −0.16 | −0.13 | −0.17 | −0.17 | −0.08 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −275.7 | −187.6 | −115.0 | −57.8 | −56.0 | −74.0 | −42.5 | −38.0 | −43.1 | −16.8 | −392.3 |
| Shares out B | 1.54 | 1.36 | 0.99 | 0.93 | 0.93 | 0.63 | 0.63 | 0.56 | 0.42 | 0.42 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 42 reconciliationsAUDITED
Reconciled in 11 of 19 fiscal years. 52 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onnot stated in the filings
Incorporated inoutside the United States — SEC code X0
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013